На главную
Результаты поиска “Polyclonal light chains in rheumatoid arthritis”
M-protein diagnostics of Multiple Myeloma patients treated with biologics
 
59:05
Speaker: J.F.M. (Hans) Jacobs (NL) Moderator: Christopher McCudden (CA) Recorded at: 27th March 2018 at 14:00 CET Treatment of multiple myeloma (MM) has substantially changed with the recent introduction of therapeutic monoclonal antibodies (mAb) which have further improved the rates and depth of clinical response. mAb therapy in MM patients has introduced new challenges in how therapy responses can be defined. On the one hand, recently approved mAb interfere with routine M-protein diagnostics. On the other hand, given the high rates of complete responses, new response categories need to be defined to measure minimal residual disease. As a reaction to these challenges research has focused on adaptations of conventional M-protein diagnostics to mitigate interference and on the introduction of novel methods that enable the identification of minimal residual disease. The aim of this e-seminar is to discuss how mAb therapy has changed both the therapeutic as well as the diagnostic landscape of MM.
Просмотров: 563 EFLM
New research on antibodies from camelids
 
02:53
Просмотров: 200 Discovery
TRACO 2018 - Radiation oncology and CAR T-cells
 
01:48:07
TRACO 2018 - Radiation oncology and CAR T-cells Air date: Thursday, October 11, 2018, 4:00:00 PM Category: TRACO Runtime: 01:48:07 Description: Radiation oncology and CAR T-cells For more information go to http://ccr.cancer.gov/training/trainee-resources/courses-workshops/traco Author: Elizabeth Nichols, MD, University of Maryland Medical Center and James N. Kochenderfer, MD, NCI, NIH Permanent link: https://videocast.nih.gov/launch.asp?26104
Просмотров: 39 nihvcast
UNL Chemistry Colloquium: John Schiel
 
55:52
John Schiel presents at the 2014 Chemistry Colloquium at University of Nebraska-Lincoln. Schiel is a research chemist at the National Institute of Standards and Technology coordinating bioanalytical efforts of the Biomanufacturing Program. He received the 2014 Early Achiever Award from the University of Nebraska-Lincoln. A native Nebraskan, he earned his bachelor's and doctoral degrees in Chemistry at UNL in 2004 and 2009, and then served as a postdoc at NIST for two years. Schiel is currently developing a recombinant IgG1κ monoclonal antibody as a National Reference Material to support the biomanufacturing industry. As part of this project, he is coordinating a round-robin characterization of the NIST mAb that includes more than 60 contributors from industry, academia and regulatory agencies.
Просмотров: 594 University of Nebraska–Lincoln